Palatin Technologies Inc - PTN EV/Sales Multiple

Palatin Technologies Inc (PTN) - corporate logo

Despite its authority in women's health therapy with the drug Vyleesi, strict insurance limits are forcing Palatin Technologies (PTN) to apply significant discounts. The company's current price-to-sales ratio reflects market expectations, where the value 1106.38 indicates the current magnitude. Business stability relies on the patent protection of unique formulas for treating sexual disorders, which create a protected niche.

PTN (Palatin Technologies) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Palatin (PTN)

Fundamental valuation:Palatin Technologies (PTN)
Finished products of Palatin Technologies Inc

For Palatin Technologies (PTN), which develops highly scalable peptide drugs, the current EV/Sales ratio allows for an assessment of the business's market value relative to revenue, excluding the impact of debt. This metric compares the total enterprise value with sales volume, helping investors understand how much the market is willing to pay for every dollar of revenue from proprietary medicines regardless of the liability structure.